Filters

Term Search
You can select from the dropdown list OR enter your own terms to refine the search.

Last Updated: 01/07/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 54 publications

Efficacy and Safety of Long-Term Continuous Nirogacestat Treatment in Adults With Desmoid Tumors: Results From the DeFi Trial.

Efficacy and Safety of Long-Term Continuous Nirogacestat Treatment in Adults With Desmoid Tumors: Results From the DeFi Trial.

Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Published: October 20, 2025

Case Report: Nirogacestat therapy induces rapid response in a patient with refractory, life-threatening desmoid tumor.

Case Report: Nirogacestat therapy induces rapid response in a patient with refractory, life-threatening desmoid tumor.

Journal: Frontiers in oncology
Published: September 27, 2025

Disproportionality Analysis of Dermatologic Adverse Events Associated with Nirogacestat: Insights from the FDA Adverse Event Reporting System (FAERS).

Disproportionality Analysis of Dermatologic Adverse Events Associated with Nirogacestat: Insights from the FDA Adverse Event Reporting System (FAERS).

Journal: Journal of the American Academy of Dermatology
Published: September 05, 2025

Repurposing nirogacestat, a gamma secretase enzyme inhibitor in desmoid tumors.

Repurposing nirogacestat, a gamma secretase enzyme inhibitor in desmoid tumors.

Journal: Future oncology (London, England)
Published: September 01, 2025

Rapid biocompatible solid phase microextraction: Nirogacestat protein binding in post dose human serum samples.

Rapid biocompatible solid phase microextraction: Nirogacestat protein binding in post dose human serum samples.

Journal: Journal of chromatography. B, Analytical technologies in the biomedical and life sciences
Published: August 29, 2025

New onset hidradenitis suppurativa and eruptive milia associated with gamma secretase inhibitor therapy in a patient with desmoid tumor: A case report.

New onset hidradenitis suppurativa and eruptive milia associated with gamma secretase inhibitor therapy in a patient with desmoid tumor: A case report.

Journal: JAAD case reports
Published: August 11, 2025

Top advances of the year: Sarcoma.

Top advances of the year: Sarcoma.

Journal: Cancer
Published: June 29, 2025

Management of Desmoid Tumors.

Management of Desmoid Tumors.

Journal: Current oncology reports
Published: June 12, 2025

Clinical Challenges and Evolving Treatments in Desmoid Fibromatosis: A Single Institution Experience.

Clinical Challenges and Evolving Treatments in Desmoid Fibromatosis: A Single Institution Experience.

Journal: Cancer investigation
Published: April 21, 2025

UPLC-LCMS-Based Method Development, Validation, Forced Degradation, and Impurity Profiling of Nirogacestat Drug Substance.

UPLC-LCMS-Based Method Development, Validation, Forced Degradation, and Impurity Profiling of Nirogacestat Drug Substance.

Journal: Current topics in medicinal chemistry
Published: April 16, 2025

Exploring Clinical Studies and the FDA Adverse Event Reporting System (FAERS) Database for nirogacestat-related Adverse Events.

Exploring Clinical Studies and the FDA Adverse Event Reporting System (FAERS) Database for nirogacestat-related Adverse Events.

Journal: Therapeutic innovation & regulatory science
Published: April 12, 2025

Dermatologic adverse events associated with gamma secretase inhibitor nirogacestat: A retrospective multicenter cohort study.

Dermatologic adverse events associated with gamma secretase inhibitor nirogacestat: A retrospective multicenter cohort study.

Journal: Journal of the American Academy of Dermatology
Published: March 15, 2025
Showing 1-12 of 54

Last Updated: 01/07/2026